Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 | O75874 | 7/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 7/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.31 |
| ▸ | LATS1 | O95835 | 1/20 | 0.30 |
| ▸ | LATS2 | Q9NRM7 | 1/20 | 0.30 |
| ▸ | IDH2 | P48735 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2833339 | 1.00 | IDH1 (0.36) | IDH1ADORA2AMAPTMAPK1HTT | |
| SCHEMBL4019944 | 1.00 | IDH1 (0.36) | IDH1ADORA2AMAPTMAPK1HTT | |
| SCHEMBL13870018 | 0.85 | ADORA2A (0.36) | IDH1ADORA2AMAPTMAPK1HTT | |
| SCHEMBL2831906 | 0.84 | HSD17B10 (0.36) | IDH1MAPK1KDM4EALDH1A1HPGD | |
| SCHEMBL2831911 | 0.84 | HSD17B10 (0.36) | IDH1MAPK1KDM4EALDH1A1HPGD | |
| SCHEMBL4018442 | 0.84 | ADORA2A (0.31) | ADORA2AMAPTKDM4EALDH1A1HPGD | |
| SCHEMBL4018930 | 0.84 | ADORA2A (0.31) | ADORA2AMAPTKDM4EALDH1A1HPGD | |
| SCHEMBL4016364 | 0.84 | ADORA2A (0.31) | ADORA2AMAPTKDM4EALDH1A1HPGD | |
| Hydrochloric Acid SCHEMBL4024763 | 0.83 | ADORA2A (0.31) | ADORA2AMAPTKDM4EALDH1A1HPGD | |
| Hydrochloric Acid SCHEMBL4024760 | 0.83 | ADORA2A (0.31) | ADORA2AMAPTKDM4EALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1663241-B1 | 5-ARYLPYRIMIDINES AS ANTICANCER AGENTS | WYETH CORP (US) | 2009-05-27 | — | — | EP | claimed |
| US-7524849-B2 | Antitumor agents to treat multiple drug resistant tumors; promoters of microtubule polymerization; etherification | WYETH HOLDINGS CORPORATION (US) | 2009-04-28 | — | — | US | claimed |
| EP-1663241-A1 | 5-ARYLPYRIMIDINES AS ANTICANCER AGENTS | Wyeth Holdings Corporation (US) | 2006-06-07 | — | — | EP | claimed |
| WO-2005030216-A1 | 5-ARYLPYRIMIDINES AS ANTICANCER AGENTS | WYETH HOLDINGS CORPORATION (US) | 2005-04-07 | — | — | WO | claimed |
| US-20050075357-A1 | 5-arylpyrimidines as anticancer agents | WYETH (US) | 2005-04-07 | — | — | US | claimed |
| US-7709637-B2 | 5-phenylpyrimidines, their preparation, intermediates for their preparation, and their use for controlling harmful fungi | BASF SE (DE) | 2010-05-04 | — | — | US | disclosed |
| EP-1663241-B1 | 5-ARYLPYRIMIDINES AS ANTICANCER AGENTS | WYETH CORP (US) | 2009-05-27 | — | — | EP | disclosed |
| US-7524849-B2 | Antitumor agents to treat multiple drug resistant tumors; promoters of microtubule polymerization; etherification | WYETH HOLDINGS CORPORATION (US) | 2009-04-28 | — | — | US | disclosed |
| US-7524849-B2 | Antitumor agents to treat multiple drug resistant tumors; promoters of microtubule polymerization; etherification | WYETH HOLDINGS CORPORATION (US) | 2009-04-28 | — | — | US | disclosed |
| US-20070088026-A1 | 5-phenylpyrimidines, their preparation, intermediates for their preparation, and their use for controlling harmful fungi | METAVANTE CORPORATION | 2007-04-19 | — | — | US | disclosed |
| US-7153860-B2 | 5-Phenylpyrimidines, methods and intermediate products for the production thereof and use of the same for controlling pathogenic fungi | BASF AKTIENGESELLSCHAFT (DE) | 2006-12-26 | — | — | US | disclosed |
| EP-1663241-A1 | 5-ARYLPYRIMIDINES AS ANTICANCER AGENTS | Wyeth Holdings Corporation (US) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005030216-A1 | 5-ARYLPYRIMIDINES AS ANTICANCER AGENTS | WYETH HOLDINGS CORPORATION (US) | 2005-04-07 | — | — | WO | disclosed |
| US-20050075357-A1 | 5-arylpyrimidines as anticancer agents | WYETH (US) | 2005-04-07 | — | — | US | disclosed |
| US-20040116429-A1 | 5-Phenylpyrimidines, methods and intermediate products for the production thereof and use of the same for controlling pathogenic fungi | BASF SE (DE) | 2004-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075357-A1 | 5-arylpyrimidines as anticancer agents | DPYD, ABCC1, ARF5 | IDH1 1004/4885ADORA2A 1489/4885MAPT 485/4885 |
| US-20070088026-A1 | 5-phenylpyrimidines, their preparation, intermediates for their preparation, and their use for controlling harmful fungi | DPYD, CBR3, RNGTT | IDH1 176/4885ADORA2A 780/4885MAPT 4342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.